Based on the Alkermes Plc stock forecast from 9 analysts, the average analyst target price for Alkermes Plc is USD 37.77 over the next 12 months. Alkermes Plc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Alkermes Plc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Alkermes Plc’s stock price was USD 28.35. Alkermes Plc’s stock price has changed by -2.14% over the past week, -2.41% over the past month and +17.20% over the last year.
No recent analyst target price found for Alkermes Plc
No recent average analyst rating found for Alkermes Plc
Company Overview Alkermes Plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, D04 C5Y6 Read Less
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products fo...Read More
Frequently Asked Questions About Alkermes Plc (ALKS) Stock
Based on ratings from 9 analysts Alkermes Plc's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 13 buy, sell and 9 hold ratings.
Unfortunately we do not have enough data on ALKS's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for ALKS is USD 37.77 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 25.
ALKS stock's Price/Earning ratio is 12.77.
Our analysis grades ALKS stock's Price / Earning ratio at D+. This means that ALKS stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ALKS may be fairly valued for its sector
The last closing price of ALKS's stock was USD 28.35.
The most recent market capitalization for ALKS is USD 4.73B.
Based on targets from 9 analysts, the average taret price for ALKS is projected at USD 37.77 over the next 12 months.
This means that ALKS's stock price may go up by +33.24% over the next 12 months.
We can't find any ETFs which contains Alkermes Plc's stock.
As per our most recent records Alkermes Plc has 2,100 Employees.
Alkermes Plc's registered address is Connaught House, Dublin, Ireland, D04 C5Y6.
You can get more information about it from Alkermes Plc's website at https://www.alkermes.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Alkermes Plc (ALKS) Stock
Based on ratings from 9 analysts Alkermes Plc's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 13 buy, sell and 9 hold ratings.
Unfortunately we do not have enough data on ALKS's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for ALKS is USD 37.77 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 25.
ALKS stock's Price/Earning ratio is 12.77.
Our analysis grades ALKS stock's Price / Earning ratio at D+. This means that ALKS stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ALKS may be fairly valued for its sector
The last closing price of ALKS's stock was USD 28.35.
The most recent market capitalization for ALKS is USD 4.73B.
Based on targets from 9 analysts, the average taret price for ALKS is projected at USD 37.77 over the next 12 months.
This means that ALKS's stock price may go up by +33.24% over the next 12 months.
We can't find any ETFs which contains Alkermes Plc's stock.
As per our most recent records Alkermes Plc has 2,100 Employees.
Alkermes Plc's registered address is Connaught House, Dublin, Ireland, D04 C5Y6.
You can get more information about it from Alkermes Plc's website at https://www.alkermes.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ALKS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
